Kymab Limited
Patent owner in reexamination·3 ex parte reexams
Kymab Limited's patents have been the subject of 3 USPTO ex parte reexaminations. ExamPat indexes the full prosecution record for each proceeding, including office-action grounds, certificate outcomes, and downstream PTAB and Federal Circuit decisions.
Filings by year
317
Outcome track record
How reexams of this owner's patents resolve: claims confirmed, amended, mixed, or fully canceled.
- Certificate outcome split across every bucket
- Claim-survival rate
Defense metrics
Claim-survival rate, average pendency, and the open/closed split across every reexam of this owner's patents.
- Survival rate of closed proceedings
- Average pendency in months
Challengers & examiners
Which requesters most often challenge this owner's patents, and which examiners decide them.
- Top requesters
- Most frequent examiners
Recent reexaminations (3)
| Control # | Filed | Patent | Title | Requester | Status |
|---|---|---|---|---|---|
| 90/014,017 | Sep 29, 2017 | 9,040,052 | Precision Medicine by Targeting Rare Human PCSK9 Variants for Cholesterol Treatment | — | Closed |
| 90/013,979 | Jul 10, 2017 | 8,951,523 | Targeting Rare Human PCSK9 Variants for Cholesterol Treatment | — | Closed |
| 90/013,963 | Jun 14, 2017 | 8,883,157 | Targeting Rare Human PCSK9 Variants for Cholesterol Treatment | — | Closed |
See the full reexam picture for Kymab Limited
Certificate outcomes, pendency, and the parties and examiners behind these cases. Free to sign up.